Palvella Therapeutics (PVLA) Other financing activities (2013 - 2026)
Palvella Therapeutics (PVLA) reported Other financing activities of $14.2 million for Q1 2026, up 474800.0% on a QoQ basis from $3000.0 in Q3 2014.
Palvella Therapeutics (PVLA) has 3 years of Other financing activities data on file, last reported at $14.2 million in Q1 2026.
- Quarterly Other financing activities changed N/A year-over-year to $14.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.3 million (up 284908.0% YoY) and the FY2025 annual result came in at $154000.0, changed N/A from the prior year.
- Other financing activities improved to $14.2 million in Q1 2026 per PVLA's latest filing, from $3000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $14.2 million in Q1 2026 and bottomed at $14.2 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.25 Mn |
| Mar 31, 2026 | 14.25 Mn |
| Sep 30, 2014 | 3,000.00 |
| Sep 30, 2014 | 3,000.00 |
| Mar 31, 2014 | 400.00 |
| Mar 31, 2014 | 400.00 |
| Dec 31, 2013 | 1,600.00 |
| Dec 31, 2013 | 1,600.00 |
| Jun 30, 2013 | 474.00 |
| Jun 30, 2013 | 474.00 |